Group 1: Company Overview and Market Conditions - The overall business operation of the company in Q3 2025 remains stable, with market demand relatively steady and sales progressing as planned [2] - The pharmaceutical manufacturing industry saw a revenue of CNY 12,275.2 billion in the first half of 2025, a year-on-year decrease of 1.2%, and a total profit of CNY 1,766.9 billion, down 2.8% [2] - Despite the overall industry pressure, the transdermal patch market is showing a positive growth trend, with sales expected to exceed CNY 7 billion in 2024, a year-on-year increase of approximately 10%, and over CNY 4 billion in the first half of 2025, up about 15% [3] Group 2: Strategic Focus and R&D Investment - The company is fully transitioning to focus on innovative drug research and development, with a core emphasis on chemical and traditional Chinese medicine innovations [4] - The estimated R&D expenditure for the year 2025 is projected to be between CNY 250 million and CNY 300 million [5] - The company is committed to enhancing its product strength and brand influence through continuous R&D, aiming to meet diverse health needs and create long-term value for investors [6][7] Group 3: Competitive Landscape and Product Development - The external pain relief market has significant growth potential, driven by increasing health demands and an aging population [6] - The JIJ02 gel shows advantages over existing acne treatments, such as lower risk of resistance and milder side effects, with plans to expand its indications in the peptide drug area [7] - Following the implementation of centralized procurement for the Loxoprofen Sodium Gel Patch, the company will adopt multi-faceted measures to stabilize its business foundation and ensure long-term growth [7]

Core Viewpoint - The company, Jiutian Pharmaceutical (300705), responded to investor inquiries on October 17, indicating that the number of shareholders and the shareholding ratio of the top ten shareholders will be disclosed in regular reports as per regulations [1] Group 1 - The company confirmed that shareholder information is disclosed in periodic reports [1]

Group 1 - The company is focusing on a strategic transformation towards innovative drug development, with a core emphasis on chemical innovative drugs and a layout for traditional Chinese medicine innovative drugs [2] - In the pain management sector, the company is developing peptide and small molecule drugs, while in the oncology sector, it is concentrating on PDC drugs [2] - The company has received clinical trial approval for JIZM01 and JIZM02, and has submitted production applications for the pepper seven pain relief gel patch [2] Group 2 - The company is optimistic about the market prospects for its anti-inflammatory and pain relief patch, primarily targeting the OTC channel, and plans to enhance sales through resource sharing and product matrix expansion [3] - The JIJ02 gel is expected to complete Phase I clinical trials by mid-next year and initiate Phase II trials, with characteristics that make it superior to existing acne treatments [4] - The company plans to expand the indications for peptide drugs and focus on new project introductions, particularly in pain and pulmonary fibrosis areas [4] Group 3 - The company is currently in the bidding phase for the eleventh batch of national drug procurement for its Loxoprofen sodium gel patch, with submission of application materials and public pricing due by October 27 [5] - The company’s e-commerce strategy is centered around the "big health category," utilizing social e-commerce platforms like Xiaohongshu, Douyin, and Kuaishou for targeted marketing [6]

Group 1: Company Strategy and Focus - The company is fully transforming to focus on innovative drug research and development, with a core emphasis on chemical and traditional Chinese medicine innovations [2][3] - Key therapeutic areas include pain management, with a focus on peptide and small molecule drugs, and oncology, specifically PDC drug development [2] - The company employs a dual approach of independent research and project acquisition to enhance its innovation capabilities and accelerate the commercialization of results [3] Group 2: Product Development and Market Outlook - The company has submitted production applications for its traditional Chinese medicine product, Jiao Qi Pain Relief Gel, which is currently under review [2] - The JIJ02 gel is expected to complete Phase I clinical trials in the first half of next year and will initiate Phase II trials thereafter [5] - The company is optimistic about the market potential for its anti-inflammatory pain relief patch, particularly due to the increasing prevalence of chronic pain among the aging population [4] Group 3: Market Strategy and Sales Channels - The sales strategy for the anti-inflammatory pain relief patch primarily targets OTC channels, with plans to enhance sales through resource sharing and product diversification [4] - The company is currently in the bidding phase for the 11th batch of national drug procurement, with submission of application materials and public pricing scheduled for October 27 [6] - The company plans to leverage e-commerce platforms like Xiaohongshu, Douyin, and Kuaishou to reach health-conscious consumers through content marketing and KOL collaborations [9]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.66% on October 9, with Nanjing New Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Haichen Pharmaceutical (300584) with a closing price of 63.81, up 13.76% and a trading volume of 155,800 shares, totaling 973 million yuan [1] - Changshan Pharmaceutical (300255) closed at 49.29, up 8.21% with a trading volume of 394,400 shares, totaling 1.916 billion yuan [1] - Conversely, Nanjing New Pharmaceutical (688189) saw a significant drop of 19.96%, closing at 9.10 with a trading volume of 32,300 shares, totaling 29.426 million yuan [2] Capital Flow - The chemical pharmaceutical sector experienced a net outflow of 1.108 billion yuan from institutional investors, while retail investors saw a net inflow of 544 million yuan [2] - The capital flow for specific stocks showed: - Changshan Pharmaceutical had a net inflow of 14.6 million yuan from institutional investors, but a net outflow of 14 million yuan from retail investors [3] - Haichen Pharmaceutical recorded a net inflow of 85.3 million yuan from institutional investors, with retail investors showing a net outflow of 68 million yuan [3]

湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万元，回购价格不超过人民币 24.98 元/股， 实施期限为自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公 司在巨潮资讯网披露的《回购股份报告书》（公告编号：2025-012）等相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关 规定，回购期间公司应当在每个月的前三个交易日内披露截至上月末的回购进展 情况。现将公司回购进展情况公告如下： 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-071 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-070 | 湖南九典制药股份有限公司 关于 2025 年第三季度可转换公司债券转股情况的公告 经深圳证券交易所（以下简称"深交所"）同意，公司可转债于 2023 年 10 月 13 日起在深交所挂牌交易，债券简称：九典转 02，债券代码：123223。 根据《深圳证券交易所创业板股票上市规则》和《湖南九典制药股份有限公 司创业板向不特定对象发行可转换公司债券募集说明书》的规定，公司可转债的 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、九典转02转股期限为2024年3月21日至2029年9月14日，最新转股价格为 14.95元/股。 2、2025年第三季度，共有116张九典转02完成转股，对应票面金额为11,600 元，转股数量为774股。 3、截至2025年第三季度末，九典转02剩余2,052,798张，对应票面金额为 205,279,800元。 根据《深圳证券交易 ...

Group 1: Strategic Focus and Innovation - The company is fully transforming to focus on innovative drug research and development, with a core direction in chemical and traditional Chinese medicine innovation [2] - Key therapeutic areas include pain management, focusing on peptide and small molecule drugs, and oncology, with a focus on PDC drug development [2] - The company employs a dual approach of independent research and project acquisition to build core technological barriers and accelerate innovation results [3] Group 2: Product Launch and Market Expectations - The ketoprofen gel patch was approved for market launch in 2023 and has entered the national medical insurance directory, being the first generic product in the market [4] - The company has optimistic market expectations for the ketoprofen gel patch and has developed new sales strategies focusing on external markets [4] Group 3: Research and Development Investment - The estimated R&D expenditure for 2025 is projected to be between 250 million and 300 million yuan [5] Group 4: Employee Incentives and Governance - The company is implementing a share repurchase plan to support future equity incentive plans, aiming to enhance governance and align interests among stakeholders [6] Group 5: New Product Highlights - The newly introduced innovative drug JIJ02 gel has broad-spectrum antibacterial properties, low cost, and is expected to have significant market competitiveness [7][8] - JIJ02 gel is anticipated to complete Phase I clinical trials by mid-next year and will initiate Phase II trials thereafter [8] Group 6: Pricing and Procurement - The company is currently in the bidding phase for the 11th batch of national drug procurement, with submission of application materials and public pricing information due by October 21 [8]

Core Viewpoint - The company announced the completion of changes to its registered capital and the revision of related articles, following the approval at the first extraordinary shareholders' meeting of 2025 held on September 9, 2025 [1] Group 1 - The company has completed the business registration change procedures and obtained a new business license issued by the Changsha Market Supervision Administration [1]

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-069 | 湖南九典制药股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于2025年9月9日召开2025 年第一次临时股东会，审议通过了《关于变更注册资本及修订<公司章程>的议案》， 具体内容详见公司在巨潮资讯网上披露的相关公告。 统一社会信用代码：91430100722520761D 类型：股份有限公司（上市、自然人投资或控股） 法定代表人：朱志宏 注册资本：伍亿零贰拾壹万贰仟叁佰伍拾伍元整 成立日期：2001 年 1 月 19 日 住所：长沙市浏阳经济技术开发区健康大道 1 号 经营范围：药品、二类医疗器械、消毒剂、化工产品、卫生用品、化妆品、 保健品、保健食品、食品、特殊医学用途配方食品、特殊膳食食品、一类医疗器 械、中医药、生物制品、植物提取物的研发；化学药品制剂、化学药品原料药、 生物药品、 ...